Our Program Pipelines

NB 1001

NB 1001 Pediatric

NB 1002

NB 1002 Crohn's

NB 1001 and NB 1001 Pediatric

Licensed from Amunix Operating Inc., NB 1001 uses Amunix’s proprietary XTEN® technology to extend the half-life of the GLP-1 peptide, allowing for once or twice-per-month dosing, thus considerably increasing convenience for patients and caregivers. NB1001 will be administered as a replacement therapy (replacing endogenous GLP-1 lost by bowel resection), in contrast to GLP-1 agonists used to treat Type 2 diabetes, which are administered at pharmacologic levels in order to lower blood sugar. Lower doses of NB1001 combined with a longer half-life will provide a differentiated, safe, effective and convenient therapeutic approach for these patients.

NB1001 is patent protected and has received orphan drug designation by the FDA.

Naia has assembled an advisory board of some of the most notable experts in the disease to help guide the development of NB 1001. They have been intimately involved in designing the Phase 1 clinical study which will start in 2018.

Naia Rare Diseases  expects to be able to initiate a pivotal clinical study during early 2019.

Once these studies are completed, NB 1001 could be approved for use by patients as early as 2021.

We believe that, when approved, NB 1001 will provide significant benefits to patients with SBS, including reduced diarrhea, significantly reduced or even eliminated TPN, and increased nutritional wellbeing.

 

NB 1001

USA - SBS Patients

NB 1001

USA - Addressable

NB 1001 Pediatric

USA - Pediatric SBS Patients

NB 1001 Pediatric

USA - Addressable

Alongside NB 1001, we are developing further, complementary drugs for the treatment of SBS and other rare GI diseases, with the ultimate aim of providing all sufferers with treatments that will allow them return to a normal, healthy life.

 

NB 1002 and NB 1002 Subset of Crohn’s

NB1002 is being developed for SBS (adult and pediatric). Using this approach we expect the concentrations of NB 1002 needed to be lower and safer than other GLP-2 approaches on the market and in development, while providing the added convenience of twice a month (instead of daily) administration. Particularly we will develop a twice a month, single dose, combination of NB 1001/NB 1002 for SBS. We believe that slowing intestinal transit with NB 1001 while increasing intestinal surface area with NB 1002 could be of significant benefit to these patients, particularly in the most severe cases.

Furthermore, NB 1002 has been shown to be effective in animal models of inflammatory bowel disease. Naia has identified a subset of these patients that would benefit from using NB 1002. This patient population does not have therapeutic alternatives available besides surgery and symptomatic therapies.

NB 1002 is patent protected.

NB 1002

USA - SBS Patients

NB 1002

USA - Addressable

NB 1002 Crohn’s

USA - Crohn's Patients

NB 1002 Crohn’s

USA - Addressable

Contact us for further information